HIV-specific immunity during structured antiviral drug treatment interruption
Related Experiment Video
Updated: Sep 23, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Ronald B Moss1, Carolyn Brandt, Wieslawa K Giermakowska
1The Immune Response Corporation, 5935 Darwin Court, Carlsbad, CA 92008, USA. shotdoc@imnr.com
Abstract:
The immunologic correlates associated with control of viremia in HIV disease are poorly understood. We hypothesized that structured antiviral drug treatment interruptions could be utilized to better understand the relationship between HIV-specific immunity and viral replication. We thus examined the effects of two 8 weeks antiviral structured treatment interruptions (STIs) in a cohort of HIV-1 chronically infected individuals on highly active antiretroviral treatment (HAART) with (n = 13) and without (n = 12) therapeutic HIV immunizations. In this study, we observed that p24 gag antigen (np24) stimulated MIP-1beta levels and T helper immune responses prior to antiviral drug discontinuation were associated with control of viremia. Stronger and earlier production of gag peptide stimulated gamma interferon was observed in the immunized group during the structured antiviral drug interruptions. These results support the concept that HIV-specific immune responses are associated with control of viremia. Further study of immune-based therapies that enhance HIV-specific immunity is warranted.
Related Concept Videos
Retrovirus Life Cycles
Immune Response Against Viral Pathogens
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
Size and Structure of Viral Genomes
Inhibitors of Viral Protein Synthesis
Antiviral Nucleoside Inhibitors
Inhibitors of Virion Maturation and Assembly

